each other, blood tests. Final diagnosis was determined by the third US expert if the 2 observers got the different conclusion. Bilateral toes, dorsal feet, ankle, knee, wrist, fingers, elbow, and shoulder were detected to find 6 features of gout suggested by OMERCT: tophus, "snow storm"-like effusion, cloudy synovium in grey scale, double-contour sign, bone erosion and Power Doppler (PD) signal. Each above positive presentations in each above range would get 1 point and the sum scores would be ranged from 0 to 84. Serum uric acid (UA) was recorded too. Results: 1) 23 female and 139 male were recruited in the program. The femalemale ratio was 1:6. Mean age and disease duration of the female subjects were elder than male ones (female:male=57.2±14.1: 44.7±14.7 years old) with longer disease duration to confim the diagnosis (female:male = 10.9:1.2 months). The average serum UA level in female was lower than male group (female:male = 413.8±162.1umol/L, 515.5±156.9umol/L, sig<0.05).
THU0422 SEL-212: ENHANCED SERUM URIC ACID CONTROL IN HYPERURICEMIC PATIENTS THROUGH SELECTIVE MITIGATION OF ANTI-DRUG ANTIBODIES AGAINST PEGSITICASE
Background: Recent EULAR recommendations for refractory gout treatment with pegylated uricase (pegloticase) acknowledge the risk of allergic reactions related to the development of anti-drug antibodies (ADAs) [1] . ADAs also affect the efficacy of treatment [2] . As a novel approach to treatment, we demonstrated that co-administration of pegsiticase (another pegylated uricase) and a synthetic vaccine particle encapsulating rapamycin (SVP-R) showed improved control of serum uric acid (sUA) in uricase-deficient mice by inducing antigen-specific immune tolerance to pegsiticase [3] . Here we describe the impact of SEL-212, a combination product of SVP-R and pegsiticase, on ADA formation and sUA levels in hyperuricemic patients in a Phase 1 open-label multicenter clinical trial. Objectives: To assess the initial safety and impact on sUA levels and ADA formation of SEL-212, which is designed to be the first non-immunogenic uricase therapy for refractory gout. Methods: Cohorts of hyperuricemic (sUA ≥6 mg/dL) patients consented to a single dose of 0.4 mg/kg pegsiticase alone, SVP-R alone (0.03-0.5-mg/kg), or 0.4 mg/kg pegsiticase co-administered with SVP-R (0.03-0.3-mg/kg; SEL-212). ADAs and sUA were assessed at baseline and 7, 14, 21, and 30 days after dosing. Results: Sixty-three patients were enrolled with a median age of 49.4 years. Mean baseline sUA was 7.4±1.3 mg/dL. Patients dosed with pegsiticase alone showed an immediate drop in sUA, which returned to baseline levels by 14-21 days in 4 of 5 subjects, correlating with the induction of ADA titers >1000. Patients treated with SVP-R alone showed no meaningful change in sUA. In contrast, patients treated with SEL-212 showed a dose-dependent inhibition of anti-uricase ADAs and corresponding decrease in sUA levels through at least day 30 after a single injection. Seven of 10 patients treated with SEL-212 at a SVP-R dose of 0.1 mg/kg showed no detectable sUA at day 30, and all 10 subjects dosed with SEL-212 at SVP-R doses of 0.15 or 0.3 mg/kg showed sustained control of sUA through at least day 30. There was a strong correlation between maintenance of low uric acid levels at day 30 and with low or no ADA titers. SEL-212 was generally well tolerated at effective dose levels. One SAE (grade 2 rash) was observed in the lowest of the three effective dose levels (0.1 mg/kg SVP-R). A second SAE was determined by the investigator to be not related to study drug. All SAEs fully resolved. No SAEs were observed with SEL-212 at the higher effective dose levels of SVP-R (0.15 or 0.3 mg/kg). Background: Ultrasonography (US) has recently been validated and used as an objective diagnostic tool for urate deposition also joint damage and was proposed as an outcome measure in gout [1-2]. Objectives: Our aim was to investigate the relationship between clinical gout activity and load of US changes. Methods: Sixty monosodium-urate-crystal-confirmed gout patients (52 men) and 36 healthy normouricemic controls were prospectively included in one centre. The relationship between clinical symptoms and US gout-related changes investigating 36 joints and 4 tendons (m. triceps and patellar) was evaluated using Spearman's correlation.
Results:
The total number of intraarticular T, periarticular T, total T, total DC, and total E found per patient on ultrasound ranged from 0-26, 0-4, 0-30, 0-29, and 0-18, accordingly.The number of acute attacks per year/per life had a significant positive correlation with the total number of intraarticular T (rs=0.518/0.652; p<0.0001), total number of intraarticular and periarticular T (rs=0.552/0.699; p<0.0001), the total number of DC (rs=0.374/0.551; p<0.01), the total number of erosions (rs=0.374/0.542; p<0.01), and the total tophus area (rs=0.420/0.549; p<0.01) measured on US per patient. Strong, positive correlation was observed between the number of subcutaneous tophi and total US tophus area (rs=0.628), total number of DC (rs=0.612) and erosions (rs=0.526), found per patient on US, all p<0.0001. Disease duration significantly positively correlated with the load of US T, E and DC (p<0.0001) in the investigated sites. There was no correlation between CRP and US, also no correlation between the uric acid concentration and US changes: total number of T (rs=0.193, p=0.139), DC (rs=0.179, p=0.170) or E (rs=0.063, p=0.634) found per patient. The tophus area measured in two first metatarsophalangeal joints (MTP) positively correlated with subcutaneous tophus count (rs=0,404; p=0,001), the US intraarticular T count (rs =0,732; p<0,0001) total US DC count (rs =0,477; p<0,0001) total intraarticular tophus area (rs =0,829; p<0,0001)and total tophus area other than first MTP joints (rs =0,603; p<0.0001). Conclusions: Ultrasonographic gout -related changes strongly positively correlate between each other and with subjective also objective signs of disease activity, increasing with disease duration in gout. The size of tophi inside the first metatarsophalangeal joints could be representative of the total body urate load and could be chosen as an outcome measure for the longitudinal gout studies. Background: Gout is due to monosodium urate (MSU) crystal deposition after chronic hyperuricemia. Although MSU crystal deposition can occur in every joint and peri-articular structure, spine involvement is scarcely reported. Dual energy computed tomography (DECT) is a performant tool to assess urate deposits, especially in deep structures such as intervertebral discs and apophyseal joints. Objectives: to describe spinal DECT features of urate monosodium deposits compared to peripheral joint DECT. Methods: Patient with gout diagnosis (MSU crystal identification by polarized microscopy or fulfilling "Nijmegen's criteria" (1)) who had undergone DECT were included from November 2012 to June 2016. Images were analyzed by
